Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Paclitaxel, administered weekly, compared to once-every-3-weeks in a trial of primary systemic (neoadjuvant) treatment for operable breast cancer was shown by Green and colleagues at M.D. Anderson and Brown University to provide comparable clinical responses but superior rates of pathological complete response (pCR) and breast conservation. Both the weekly and q3 week regimens were followed by 4 cycles of fluorouracil/doxorubicin/cyclophosphamide (FAC).

Weekly Neoadjuvant Paclitaxel for Breast Cancer